BMP-7
BMP-7 (Bone Morphogenetic Protein 7), also known as Osteogenic Protein-1 (OP-1), is a 139 amino acid growth factor in the TGF-beta superfamily that promotes bone formation, renal protection, and cartilage repair. It received FDA Humanitarian Device Exemption for treatment of recalcitrant long bone nonunions.
BMP-7 is a potent osteoinductive growth factor belonging to the transforming growth factor-beta (TGF-beta) superfamily. Originally identified for its ability to induce ectopic bone and cartilage formation, BMP-7 plays critical roles in skeletal development, kidney organogenesis, and tissue homeostasis.
Overview
Bone Morphogenetic Proteins were first described by Marshall Urist in 1965 when he demonstrated that demineralized bone matrix could induce new bone formation at ectopic sites. BMP-7 was subsequently cloned and characterized in the early 1990s as one of over 20 members of the BMP family. Unlike many BMPs that function primarily in skeletal tissues, BMP-7 has a distinctive dual role in both bone formation and kidney development, with high expression in the adult kidney where it maintains epithelial phenotype and opposes fibrosis.
The mature BMP-7 protein is processed from a larger precursor and functions as a disulfide-linked homodimer. It signals through type I (ALK2, ALK3, ALK6) and type II (BMPRII, ActRIIA, ActRIIB) serine/threonine kinase receptors, activating the canonical Smad1/5/8 pathway as well as non-canonical MAPK signaling cascades.
Mechanism of Action
BMP-7 exerts its effects through several key signaling pathways:
- Smad1/5/8 canonical signaling: BMP-7 binds type II receptors (BMPRII/ActRIIA), which recruit and phosphorylate type I receptors (ALK2/3/6). Activated type I receptors phosphorylate Smad1/5/8, which complex with Smad4 and translocate to the nucleus to activate osteogenic gene transcription including Runx2, Osterix, and osteocalcin
- Anti-fibrotic TGF-beta antagonism: In renal tissue, BMP-7 directly counteracts TGF-beta1-induced epithelial-to-mesenchymal transition (EMT), preserving E-cadherin expression and maintaining tubular epithelial phenotype
- Mesenchymal stem cell recruitment: BMP-7 promotes chemotaxis and osteogenic differentiation of mesenchymal progenitor cells at fracture sites, driving them toward the osteoblast lineage
- Chondrogenic induction: BMP-7 stimulates proteoglycan and type II collagen synthesis in articular chondrocytes, supporting cartilage matrix homeostasis
Reconstitution Calculator
Reconstitution Calculator
Calculate your peptide dosing
Set up a clean workspace with all supplies ready.
7x / week for weeks
Research
Bone Healing and Nonunion Fractures
BMP-7 (OP-1) has been most extensively studied for its ability to heal recalcitrant nonunion fractures. The landmark clinical trial by Friedlaender et al. (2001) demonstrated that OP-1 Implant (rhBMP-7 on a type I collagen carrier) was equivalent to autologous bone graft for tibial nonunion repair, without the donor-site morbidity. This led to FDA Humanitarian Device Exemption (HDE) approval in 2001 for long bone nonunions where autograft has failed or is not feasible.
The OP-1 Putty formulation, combining rhBMP-7 with collagen and carboxymethylcellulose, received a second HDE for revision posterolateral lumbar spinal fusion. Vaccaro et al. (2008) reported outcomes comparable to autograft in this challenging clinical setting.
Renal Fibrosis and Kidney Protection
BMP-7 has emerged as a critical renal protective factor. Zeisberg et al. (2003) demonstrated that systemic administration of rhBMP-7 reversed established renal fibrosis in multiple mouse models of chronic kidney disease by counteracting TGF-beta1-driven EMT. BMP-7 restores E-cadherin expression, reduces alpha-smooth muscle actin, and reverses the fibroblast phenotype back to functional epithelium.
In acute kidney injury models, BMP-7 accelerates tubular regeneration and reduces inflammation, suggesting both preventive and therapeutic potential in renal disease.
Spinal Fusion
Clinical application in spinal fusion has shown mixed results. While OP-1 demonstrated efficacy in revision posterolateral fusion, outcomes in primary anterior lumbar interbody fusion were less consistent. The variable results highlight the importance of local biology, carrier systems, and dosing in BMP-7 clinical applications.
Cartilage Repair
BMP-7 stimulates articular chondrocyte metabolism and matrix synthesis. Chubinskaya et al. (2007) showed that BMP-7 enhances proteoglycan production and counteracts the catabolic effects of IL-1 and fibronectin fragments in human articular cartilage explants. Unlike BMP-2, which can induce chondrocyte hypertrophy and terminal differentiation, BMP-7 promotes a stable chondrocyte phenotype more suitable for articular cartilage maintenance.
Safety Profile
BMP-7 (OP-1) has a generally favorable safety profile in orthopedic applications when used at approved doses and anatomical sites. The most common adverse effects are localized swelling and heterotopic bone formation outside the intended surgical site. Unlike BMP-2, BMP-7 has not been associated with the same degree of inflammatory complications in clinical use.
Antibody formation against rhBMP-7 has been reported in a subset of patients (up to 38% in some studies), though clinical significance remains unclear, as antibody presence has not correlated with adverse outcomes or reduced efficacy in published data.
Clinical Research Protocols
- Dosing: OP-1 Implant contains 3.5 mg rhBMP-7 per device on 1 g bovine type I collagen carrier
- OP-1 Putty: 3.5 mg rhBMP-7 on collagen with 230 mg carboxymethylcellulose
- Duration: Single intraoperative application
- Routes: Surgical implantation at fracture/fusion site
Pharmacokinetic Profile
BMP-7 — Pharmacokinetic Curve
Surgical implant (collagen carrier), Recombinant injectionQuick Start
- Route
- Surgical implant (collagen carrier), Recombinant injection
Interactions
Peptide Interactions
BMP-2/BMP-7 heterodimers demonstrate superior osteogenic potency compared to either homodimer alone. BMP-2/7 heterodimers form more ectopic bone than BMP-2 alone in rat models. Critically, BMP-2/7 heterodimers are more resistant to Noggin antagonism than homodimers, which may explain their enhanced in vivo efficacy. Engineered BMP2/7 extracellular vesicles showed superior bone formation capacity compared to BMP2 alone (Zhu et al., 2006; Nature npj Regen Med, 2025).
BMP-7 and GDF-11 are both members of the TGF-beta superfamily but signal through partially distinct receptor combinations. BMP-7 acts through BMPR2/ALK2/ALK6 and Smad1/5/8, while GDF-11 signals through ActRIIB/ALK4/ALK5 and Smad2/3. They have complementary roles — BMP-7 in osteogenesis and anti-fibrosis, GDF-11 in neurogenesis and muscle regeneration. No direct antagonism documented.
GHK-Cu modulates expression of multiple TGF-beta superfamily genes including BMPs. Both promote tissue repair through distinct mechanisms — BMP-7 through Smad1/5/8 osteogenic signaling and GHK-Cu through broad gene expression modulation affecting ~32% of human genes. GHK-Cu may support BMP-7 activity by modulating the tissue microenvironment. No antagonistic interactions reported.
BMP-7 directly opposes TGF-beta signaling in mesangial cells by reducing nuclear accumulation of Smad3 and blocking transcriptional upregulation of TGF-beta/Smad3 fibrotic targets. BMP-7 signals through Smad1/5/8 while TGF-beta signals through Smad2/3, representing antagonistic arms of the TGF-beta superfamily. BMP-7 inhibits TGF-beta-driven fibrogenesis by preventing PAI-1 upregulation and matrix degradation suppression. Concurrent use may result in unpredictable signaling outcomes (Wang & Bhatt, 2004).
What to Expect
What to Expect
Rapid onset expected; half-life of ~30 minutes (circulating) indicates fast-acting pharmacokinetics
Due to short half-life (~30 minutes (circulating)), effects are expected per-dose; consistent daily administration maintains therapeutic levels
Regular administration schedule required; effects are dose-dependent and do not persist between doses
Quality Indicators
What to look for
- Well-established safety profile
- Extensive peer-reviewed research base
Frequently Asked Questions
References (8)
- [8]Tseng YH et al. New role of bone morphogenetic protein 7 in brown adipogenesis and energy expenditure. Nature (2008)
- [3]
- [6]Tsang ML et al. Characterization of recombinant bone morphogenetic protein-7 (BMP-7/OP-1). Growth Factors (1996)
- [4]
- [1]Friedlaender GE et al. Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions. J Bone Joint Surg Am (2001)
- [5]Vukicevic S et al. The clinical use of bone morphogenetic proteins revisited: a novel biocompatible carrier device OSTEOGROW for bone healing. Int Orthop (2014)
- [7]Luo G et al. BMP-7 is an inducer of nephrogenesis, and is also required for eye development and skeletal patterning. Genes Dev (1995)
- [2]Zeisberg M et al. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med (2003)
BMP-2
BMP-2 (Bone Morphogenetic Protein 2) is a 114 amino acid osteoinductive growth factor in the TGF-beta superfamily, best known as the active component of INFUSE Bone Graft (Medtronic) for spinal fusion and fracture repair. It is the most potent single osteoinductive factor identified, though clinical use is complicated by dose-dependent inflammatory side effects.
BNP (B-type Natriuretic Peptide)
B-type Natriuretic Peptide (BNP) is a 32-amino acid cardiac hormone secreted by ventricular cardiomyocytes in response to myocardial wall stress and volume overload. BNP and its inactive fragment NT-proBNP serve as critical biomarkers for heart failure diagnosis and prognosis, while recombinant BNP (nesiritide) has been investigated as a therapeutic agent for acute decompensated heart failure.